Background information
SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), also known as novel coronavirus 2019-nCoV, causes fever, severe respiratory illness and can lead to life threatening pneumonia. The first cases of this disease, termed COVID-19 for coronavirus disease 2019, have been detected in December 2019 Wuhan, China.
SARS-CoV-2 Prot_N stands for the nucleocapsid phosphoprotein of SARS-CoV-2. This protein is responsible for the packaging of the genome of coronaviruses and, thus plays a role during replication, transcription as well as virion assembly. Therefore, the nucleocapsid phosphoprotein (“N”) of SARS-CoV-2 has been suggested as possible target for vaccine development.
Applications
PepTivator
® SARS-CoV-2 Prot_N – research grade has been specifically developed for
in vitro stimulation of SARS-CoV-2–specific T cells. Peptides of 15 amino acids in length and 11 amino acids overlap represent an optimized solution for stimulating both CD4
+ and CD8
+ T cells in various applications, including:
- Detection and analysis of SARS-CoV-2–specific CD4+ and CD8+ effector/memory T cells in PBMCs by MACS® Cytokine Secretion Assays, intracellular cytokine staining, or other technologies.
- Isolation of viable SARS-CoV-2–specific CD4+ T cells with the CD154 MicroBead Kit, or of viable CD4+ and CD8+ T cells using MACS Cytokine Secretion Assay – Cell Enrichment and Detection Kits. Subsequently, cells can be expanded for generation of T cell lines.
- Generation of SARS-CoV-2–specific CD4+ and CD8+ effector/ memory T cells from naive T cell populations.
- Pulsing of antigen-presenting cells e.g. for research on dendritic cell vaccination.
More information regarding the work with antigen-specific T cells can be found in the T cell application section.